News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
ALK-Abello A/S's ACARIZAX Data Results In Significant Change To The GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended As A Treatment Option In Patients With House Dust Mite Allergic Asthma 2/27/2017
Shire (SHPG) Release: CHMP Recommends EU Conditional Marketing Authorisation For Natpar (Parathyroid Hormone) For Patients With Chronic Hypoparathyroidism 2/27/2017
ASIT Biotech Will Publish The Results Of The Phase III Clinical Trial With Its Gp-ASIT+ Product Candidate For Treating Grass Pollen Rhinitis On 28 February, 2017 2/27/2017
NoNO, Inc Initiates Phase III Study Of NA-1 For Acute Ischemic Stroke 2/27/2017
Auris Med (EARS) Receives FDA Fast Track Designation For AM-111 In Acute Sensorineural Hearing Loss 2/24/2017
Novartis AG (NVS)'s Cancer Drug Gets a Fast Track Ticket From the FDA 2/23/2017
VBI Vaccines Receives Positive Response From Health Canada’s Initial Evaluation Of The Proposed Sci-B-Vac Phase III Clinical Program 2/22/2017
GenSight Biologics Completes Enrollment Of REVERSE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 2/21/2017
AstraZeneca PLC (AZN) Investors Pumped as Breast Cancer Drug Sails Through Phase III Trial 2/20/2017
Janssen-Cilag International NV (JNJ) Presents Newly-Published Data On The Use Of ZYTIGA (Abiraterone Acetate) Plus Prednisone In The Real-World, Outside The Clinical Trial Setting1 2/17/2017
Takeda (TKPYY) And TiGenix Report New Data Highlighting Maintenance Of Long-Term Remission Of Complex Perianal Fistulas In Crohn’s Disease Patients With Cx601 2/17/2017
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017
Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug 2/17/2017
City of Hope To Manufacture NurOwn For BrainStorm Cell's Phase III ALS Clinical Trial 2/16/2017
Roche (RHHBY) Faces Off With Itself for $9 Billion Breast Cancer Drug Business 2/15/2017
First Patient Enrolled In NovoCure’s Phase III Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Gilead (GILD) Looks Over Its Shoulder as GlaxoSmithKline (GSK) Gains Ground With New HIV Phase III Trial Data 2/14/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In BEKINDA Phase III Study For Acute Gastroenteritis 2/13/2017
Neurocrine Biosciences (NBIX) Nabs North American Rights to Bial's ONGENTYS 2/10/2017
H. Lundbeck A/S (LUN.CO) Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant (AXON) 2/8/2017
Onxeo: Information On ReLive Trial Design And Role Of Its Data Safety And Monitoring Board 2/8/2017
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Mithra Pharmaceuticals Completes Recruitment For European Phase III Estelle Study 2/7/2017
Biofrontera AG Reports Positive Phase III Results For Ameluz In Combination With Daylight-PDT 2/7/2017
Why Struggling Alkermes (ALKS) Could Make a Comeback in 2017 2/7/2017
AstraZeneca PLC (AZN) Quietly Kills Some Programs 2/6/2017
Kiadis Pharma Issues Clinical And Regulatory Progress Update On ATIR101 And ATIR201 2/6/2017
Sobi - Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy Alprolix In Children With Haemophilia B Published In The Lancet Haematology 2/2/2017
Nabriva Confirms No Sample Size Adjustment Required For LEAP 1 Phase III Trial Of Lefamulin In Community Acquired Bacterial Pneumonia 2/2/2017
Motif BioSciences, Inc. Phase 3 Clinical Trial Finishes Patient Treatment Phase 1/31/2017
Celgene (CELG) Receives Positive CHMP Opinion To Expand REVLIMID (Lenalidomide) Indication As Monotherapy For The Maintenance Treatment Of Patients With Newly Diagnosed Multiple Myeloma (MM) After Autologous Stem Cell Transplantation 1/27/2017
Foresee Pharma Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer 1/27/2017
Myovant Release: Initiates Phase 3 Clinical Program Of Relugolix In Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids 1/25/2017
ImmuPharma plc (IMM.L) Release: Company Update On Lupuzor Pivotal Phase III Study Full Analysis Of Patient Recruitment 1/25/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
OSE Immunotherapeutics Release: Company Announces That The Independent Data Monitoring Committee (IDMC) Recommends Continuation Of Pivotal Phase 3 Clinical Trial Of Tedopi In Non-Small Cell Lung Cancer 1/24/2017
Onxeo Release: Company Completes Enrollment In Phase 3 Study Of Livatag For The Treatment Of Hepatocellular Carcinoma 1/24/2017
Actelion (ALIOF.PK) Release: Amid Takeover Talks With Johnson & Johnson (JNJ), The Company's Hypertension Drug Flunks Key Phase III Test 1/23/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing 1/19/2017
How This Israeli Biotech Could be a Threat to Celgene (CELG) 1/18/2017
AstraZeneca PLC (AZN) Release: Biopharma Rejigs Primary Endpoints for Mystic Lung Cancer Trial 1/17/2017
Alcobra (ADHD) Release: Company Stock Decimated As ADHD Drug Flunks Phase III Test 1/17/2017
Allergan (AGN), Gedeon Richter (RIG2.F) Release: Companies Show Off Late-Stage Uterine Fibroids Data 1/17/2017
Pluristem Therapeutics (PSTI) Release: Company Receives Clearance From Germany To Initiate Its Multinational Phase III Trial In Critical Limb Ischemia Targeting Early Conditional Marketing Approval 1/17/2017
Shionogi Release: Pharma's Investigators are Prepping a FDA App for New Antibiotic After Positive Trial 1/13/2017
Starpharma Release: VivaGel BV Granted QIDP And Fast Track Designation By U.S. FDA 1/12/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Pluristem Therapeutics (PSTI) Release: Jumps as the FDA Clears Critical Limb Ischemia Trial 1/10/2017
RedHill Biopharma (RDHL) Release: Pharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection 1/10/2017
Pluristem Therapeutics (PSTI) Release: Company’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA 1/10/2017
Alcobra (ADHD) Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program 1/9/2017
Sun Pharma (SUNPHARMA.NS) Announces Positive Topline Results Of Confirmatory Phase-3 Clinical Trial For Seciera For Treatment Of Dry Eye 1/4/2017
JAMA Publishes Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Trastuzumab Phase 3 Data 12/27/2016
BeiGene (BGNE) Starts Global Phase III Trial Of BTK Inhibitor 12/27/2016
Chugai Pharma's Bispecific Antibody "Emicizumab" For Hemophilia A Meets Primary Endpoint In Phase lll Study 12/22/2016
Roche (RHHBY) Takes a Win as Emicizumab Hemophilia Drug Succeeds in Phase III 12/22/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Receives Positive Nice Recommendation For Adults With Psoriatic Arthritis 12/22/2016
After Failed Phase III, Auven to Terminate the KIACTA Program 12/21/2016
Octapharma AG Presents Key Data With Nuwiq In Previously Untreated Patients From The Nuprotect Study At American Society of Hematology (ASH) Annual Meeting In San Diego, USA 12/21/2016
Kiadis Pharma Provides Update On Second Dose Trial (CR-AIR-008) With ATIR101 12/21/2016
Akebia (AKBA) Forges $1B U.S. Deal with Otsuka Pharma on Late-Stage Drug 12/20/2016
Theravance Biopharma (TBPH) Highlights Initiation Of Phase 3 Study Of The Closed Triple In Patients With Asthma By GlaxoSmithKline (GSK) And Innoviva 12/20/2016
Janssen Sciences Ireland UC Release: Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen 12/20/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance 12/20/2016
Nabriva Achieves 60% Randomization Target In LEAP 1 Phase 3 Trial In Community Acquired Bacterial Pneumonia 12/20/2016
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis 12/20/2016
Primary Endpoint Met in ViiV Healthcare's Two Phase III Trials of Two-Drug HIV Treatment Regimen 12/20/2016
PHARNEXT Completes Patient Enrollment In International Pivotal Phase 3 Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 12/20/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index 12/19/2016
Grunenthal Receives Breakthrough Therapy Designation From U.S. FDA For Neridronic Acid For The Treatment Of CRPS 12/16/2016
Flamel Technologies (FLML) Doses First Patient In REST-ON Phase III Trial Of FT218 for Excessive Daytime Sleepiness & Cataplexy 12/16/2016
Dermira (DERM) Release: Second CIMZIA (Certolizumab Pegol) Phase III Trial Meets Co-Primary Efficacy Endpoints In Patients With Moderate-To-Severe Chronic Plaque Psoriasis 12/8/2016
Regeneron (REGN) And Sanofi (SNY)i Announce Marketing Authorization Application For Dupixent (Dupilumab) Accepted For Review By The EMA 12/8/2016
Valeant (VRX) Announces Phase 3 Results For Psoriasis Treatment IDP-118 12/8/2016
Horizon Pharma (HZNP) Craters as Rare Neuromuscular Drug Flunks Late-Stage Study 12/8/2016
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016
China-Prevalent Form Of NSCLC Responds To AstraZeneca PLC (AZN) Drug 12/7/2016
Auris Med (EARS) On Track To Resume Enrollment Of Keyzilen Tinnitus Program Following Regulatory Feedback 12/6/2016
Celgene (CELG) Release: ABOUND Data Presented At The World Conference On Lung Cancer Further Explores Safety And Efficacy Of ABRAXANE For Challenging Patient Populations 12/6/2016
Theravance Biopharma (TBPH) Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline (GSK) And Innoviva 12/5/2016
GW Pharma (GWPH) Announces New Epidiolex® (CBD) Positive Phase III Data In Dravet Syndrome And Lennox-Gastaut Syndrome 12/5/2016
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016
GW Pharma (GWPH) Announces Epidiolex (Cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting 12/1/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy 11/29/2016
Santen Pharma Announces Phase III SAKURA Program Topline Results In Patients With Non-Infectious Uveitis Of The Posterior Segment 11/28/2016
Intec Pharma Enters Into Agreement With The Michael J. Fox Foundation Around Its Phase III Trial Recruitment 11/28/2016
ADImmune Corporation Begins Shipments To EU And Phase III Trial In Europe 11/23/2016
Galapagos (GLPG.BR) Release: Phase 3 Study With Filgotinib Initiated In Crohn's Disease 11/23/2016
AstraZeneca PLC (AZN) Catches a Break as the FDA Lifts Hold on Head And Neck Cancer Trials 11/22/2016
Onxeo Announces 9th Positive DSMB Recommendation To Continue Livatag Relive Phase III Trial In HCC 11/21/2016
Long-Term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results And Demonstrates Superior Two- And Four-Year Survival Rates 11/18/2016
No Early Success for Regeneron (REGN) and Sanofi (SNY)'s Cholesterol Drug Praluent 11/17/2016
Grunenthal Has Acquired US-Based Thar Pharma To Expand Its Development Portfolio Of Treatment Options For CRPS (Complex Regional Pain Syndrome), A Serious, Disabling Orphan Disease 11/17/2016
Amgen (AMGN) and Novartis AG (NVS) Keep Lead in Migraine Drug Race on Positive Phase III Data 11/17/2016
Sanofi Genzyme (SNY) Release: Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease To Begin In The UK 11/17/2016
NovoCure Presents Interim STELLAR Results At IASLC Suggesting Treatment With Tumor Treating Fields Plus Chemotherapy May Extend Survival Of Patients With Mesothelioma 11/17/2016
Regeneron (REGN) And Sanofi (SNY) Present Results From Phase 3 MONARCH Study Of Investigational Sarilumab At American College of Rheumatology Annual Meeting 11/16/2016
GlaxoSmithKline (GSK)'s Benlysta (Belimumab) Shows Sustained Benefits In Patients With SLE 11/16/2016
Boehringer Ingelheim Release: Updated Phase III Results Reinforce Safety And Efficacy Of Praxbind (idarucizumab) In Urgent Situations 11/16/2016
Braeburn Pharma And Camurus Announce Positive Top-Line Phase 3 Results For Long-Acting Buprenorphine (CAM2038) For Treatment Of Opioid Addiction 11/14/2016
GlaxoSmithKline (GSK) Announces Positive Results In Fourth Consecutive Pivotal Trial Of Benlysta (Belimumab) In SLE 11/14/2016
Boehringer Ingelheim Release: Patient Enrollment Completed For RE-DUAL PCI Study Assessing Dabigatran In Atrial Fibrillation Patients After PCI With Stenting 11/11/2016
Genmab A/S (GEN.CO) Announces Phase III Study Of Daratumumab In Combination With Carfilzomib In Multiple Myeloma 11/10/2016
RedHill Biopharma (RDHL) Reports Positive FDA Type B Meeting on RHB-105 For H. pylori Infection Ahead Of Confirmatory Phase III Study 11/10/2016
Intec Pharma To Sponsor Investigator Meeting For Pivotal Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients 11/10/2016
Immunocore Presents Positive Monotherapy Data In Uveal Melanoma At The Society For Melanoma Research (SMR) 2016 Congress 11/9/2016
NovoCure Announces 38 Presentations On Tumor Treating Fields At 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology 11/7/2016
Intec Pharma Announces Protocol Amendment To Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients 11/7/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
Innocoll (INNL) Slammed on Flunked Phase III Diabetic Foot Infection Trials 11/4/2016
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug 11/3/2016
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections 11/3/2016
RedHill Biopharma (RDHL) Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA And Expected Timing Of Top-Line Results 11/3/2016
Neurim Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase III Trial Of Paediatric Prolonged-Release Melatonin (“Pedprm”) For Sleep Disturbances In Children With Autism Spectrum Disorders (ASD) 11/2/2016
Novartis AG (NVS)' Breast Cancer Contender Gets a Fast Track Ticket to the FDA, Will Take on Pfizer (PFE) 11/1/2016
AstraZeneca Canada (AZN) Release: Lynparza (Olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit For Women With Ovarian Cancer 11/1/2016
Can-Fite BioPharma (CFBI) Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA 11/1/2016
The EMA Accepts To Assess The Marketing Authorization Application From PharmaMar For Aplidin 10/28/2016
AstraZeneca PLC (AZN) Breathes a Sigh of Relief as Lynparza Delays Ovarian Cancer Progression in Phase III Test 10/26/2016
Boehringer Ingelheim’s Adalimumab Biosimilar Candidate Shows Similar Efficacy And Safety Profile To Humira In Pivotal Phase III Study 10/26/2016
GlaxoSmithKline (GSK) Terminates Development of Losmapimod for COPD 10/26/2016
Faron Pharmaceuticals Ltd. Release: First Traumakine Phase III Patient In Japan Recruited For The Treatment Of Acute Respiratory Distress Syndrome And Update On Pan-European Phase III Traumakine Trial 10/24/2016
How 3 Huge Discoveries in 2016 are Moving Us Closer to a Breast Cancer Cure 10/24/2016
Theravance Biopharma (TBPH) And Mylan (MYL) Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 10/20/2016
MicuRx Pharma Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA 10/20/2016
PAION AG: Positive Remimazolam Phase III Colonoscopy Results Presented At The 2016 American College of Gastroenterology Annual Scientific Meeting 10/19/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
Takeda (TKPYY) Showcases Continued Commitment In Hodgkin Lymphoma During 10th International Symposium On Hodgkin Lymphoma (ISHL) 10/18/2016
Shire (SHPG) Granted EU Marketing Authorization Of Onivyde, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV),For The Treatment Of Metastatic Adenocarcinoma Of The Pancreas In Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy 10/18/2016
Ferring Pharma Receives Positive CHMP Opinion For REKOVELLE (Follitropin Delta) 10/17/2016
Starpharma Release: Enrolment Complete For Phase 3 VivaGel BV-R Program 10/13/2016
OncoGenex (OGXI) Announces Results From the Phase III ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 10/13/2016
Daiichi Sankyo Announces First Patient Enrolled In Phase 3 QuANTUM-First Trial Investigating Quizartinib In Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia 10/11/2016
Novartis AG (NVS)-Backed Gamida Cell Nabs Breakthrough Tag for NiCord 10/11/2016
Tesaro (TSRO) Jumped on PARP Ovarian Cancer Win Vs. AstraZeneca PLC (AZN), AbbVie (ABBV) 10/11/2016
Genmab A/S (GEN.CO) Release: U.S. FDA Grants Priority Review For Daratumumab In Relapsed Multiple Myeloma 10/10/2016
Flamel Technologies (FLML) Reaches Agreement With FDA On Protocol For Phase III Pivotal Trial Of FT218 10/7/2016
RedHill Biopharma (RDHL) Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017 10/6/2016
Hanyang University Guri Hospital: CIK Treatment Extends Progression-free Survival Of Glioblastoma Patients By 1.5 Times 10/5/2016
Chugai Pharma's ACTEMRA/RoACTEMRA Receives Breakthrough Therapy Designation From U.S. FDA For Giant Cell Arteritis 10/5/2016
Chugai Pharma's Alecensa Receives Breakthrough Therapy Designation From FDA For First-Line Treatment Of ALK Positive Non-Small Cell Lung Cancer 10/4/2016
infirst Healthcare Announces Positive Phase III Results Of Its Lipid Formulated Ibuprofen Capsules (BC1054) 10/4/2016
MorphoSys AG Announces That Its Licensee Janssen R&D Reports Positive Results From A Phase 3 Study Of Guselkumab In Plaque Psoriasis 10/4/2016
Regeneron (REGN), Sanofi (SNY) Tout Phase III Dupixent Data 10/3/2016
Bay Area Dermira (DERM)'s CImzia Meets Co-Primary Endpoints in Key Phase III Study 10/3/2016
FDA Slaps Clinical Hold on Alcobra (ADHD)'s Late Stage ADHD Study 9/29/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Begins Patient Enrollment In North America And Europe In Two Phase 3 Studies Of MOB-015 In Onychomycosis 9/28/2016
Galapagos (GLPG.BR) Release: Successful Completion Of Regulatory Consultations To Progress Filgotinib To Phase 3 In Inflammatory Bowel Disease 9/28/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Studies Of JZP-110 Evaluating Excessive Sleepiness In Obstructive Sleep Apnea 9/27/2016
GW Pharma (GWPH)'s Cannabis-Derived Drug Successful in Third Late-Stage Epilepsy Study 9/26/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle 9/23/2016
Armed With Fresh Phase III Data, Novartis AG (NVS) Eyes First-Line Use for Lung Cancer Drug Zykadia 9/23/2016
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016
Teva (TEVA) Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD) 9/22/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne 9/20/2016
FDA Takes Back Special Protocol Assessment for Active Biotech (BTPC)'s Laquinimod 9/19/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016
Novo Nordisk A/S (NVO)'s New Diabetes Med Semaglutide Slashes Heart Disease Risk 9/16/2016
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials 9/16/2016
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine 90% Effective in People Over Age 70 9/15/2016
Innovent Biologics Starts China Trials of Two Biologic Drug Candidates 9/15/2016
GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy 9/8/2016
Boehringer Ingelheim Release: New Analysis Showed Dose Adjustment Of Giotrif (Afatinib) Improved Tolerability Without An Apparent Impact On Efficacy In Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer 9/8/2016
Theravance Biopharma (TBPH) Touts Significant Data from Pivotal Phase III FULFIL Study 9/8/2016
Takeda (TKPYY) Initiates Global Phase III Clinical Trial (TIDES) Of Dengue Vaccine Candidate (TAK-003) 9/7/2016
AstraZeneca PLC (AZN)'s Asthma Candidate Does Well in Final Late-Stage Test 9/6/2016
vasopharm BIOTECH GmbH Announces Enrollment Of First Patient In Phase III Traumatic Brain Injury (TBI) Trial 9/6/2016
Faron Pharmaceuticals Ltd. Release: Interim Results 2016: Progress Continued In Traumakine Phase III And With Clevegen Indications Extended 9/6/2016
Boehringer Ingelheim Release: New Data: Spiolto Respimat Significantly Improves Exercise Capacity In People With COPD 9/6/2016
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Fulfil Study Of Closed Triple Combination Therapy Ff/Umec/Vi Versus Symbicort Turbohaler In COPD At ERS International Congress 9/6/2016
Boehringer Ingelheim Release: Tiotropium Respimat Improved Lung Function In Children With Asthma Aged 6-17 And Is Well-Tolerated Compared To Placebo In Children Aged 1-171-5 9/6/2016
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016
Adocia's Foot Ulcer Med Flunks Phase III Test 8/26/2016
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016
Galapagos (GLPG.BR) Release: Finch Filgotinib Phase 3 Program Initiated In Rheumatoid Arthritis 8/23/2016
Mezzion (140410.KQ) And NHLBI Initiate Enrollment In A Pivotal Phase 3 Clinical Trial Of Udenafil In Adolescents With Fontan Surgical Palliation - An Orphan Drug Indication 8/22/2016
Auris Med (EARS)'s Tinnitus Drug Misses Main Goals in Study; Shares Sink 8/18/2016
Indivior Shows Off Late-Stage Opiod Addiction Trial Data 8/17/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study 8/17/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
OncoGenex (OGXI) Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study Fails 8/16/2016
Acacia Pharma Announces Positive Results From A Pivotal Phase 3 Trial Of BAREMSIS For The Treatment Of Post-Operative Nausea & Vomiting 8/12/2016
Resverlogix (RVX.TO) Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 8/11/2016
Ascendis Pharma A/S Initiates Phase 3 Registration Trial For TransCon Growth Hormone In Children With Growth Hormone Deficiency 8/11/2016
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016
Eisai Company (ESALY.PK) Release: U.S. FDA Confirms Sufficient Data To Advance Investigational Bace Inhibitor E2609 For Treatment Of Early Alzheimer’s Disease To PHASE III 8/10/2016
ThromboGenics NV (TBGNF) 2-Year OASIS Study Results Published In Ophthalmology, Journal Of The American Academy Of Ophthalmology (AAO) 8/8/2016
Allergan (AGN), Gedeon Richter (RIG2.F) Face Setback in Cariprazine Antidepressant Trial 8/5/2016
Amarin (AMRN) And FDA Reaffirm Concurrence On REDUCE-IT Through Special Protocol Assessment Agreement Amendment 8/4/2016
FDA Bestows Novartis AG (NVS)'s Breast Cancer Pill With Breakthrough Tag 8/3/2016
Sanofi (SNY) And Regeneron (REGN) Announce EMA Acceptance For Review Of Marketing Authorisation Application For Sarilumab 8/1/2016
Eisai Company (ESALY.PK) Presents Results Of Additional Analysis Of Phase III Study Of Anticancer Agent Halaven At 14th JSMO Annual Meeting Plenary Session 8/1/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma 8/1/2016



//-->